Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Working Capital Changes (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Other Working Capital Changes for 5 consecutive years, with $552000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 606.42% to $552000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 248.16% year-over-year, with the annual reading at $2.3 million for FY2025, 248.16% up from the prior year.
  • Other Working Capital Changes hit $552000.0 in Q4 2025 for Krystal Biotech, down from $1.0 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.7 million in Q4 2021 to a low of -$1.4 million in Q2 2021.
  • Historically, Other Working Capital Changes has averaged $222250.0 across 5 years, with a median of $62500.0 in 2023.
  • Biggest YoY gain for Other Working Capital Changes was 629.13% in 2024; the steepest drop was 23900.0% in 2024.
  • Year by year, Other Working Capital Changes stood at $1.7 million in 2021, then decreased by 4.8% to $1.6 million in 2022, then crashed by 82.14% to $294000.0 in 2023, then plummeted by 137.07% to -$109000.0 in 2024, then skyrocketed by 606.42% to $552000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for KRYS at $552000.0 in Q4 2025, $1.0 million in Q3 2025, and $76000.0 in Q2 2025.